EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Recent Searches
Life Sciences industry
Unleash holistic innovation for improved health outcomes and shareholder value.
Our latest thinking on the Life Sciences industry
How life sciences legal departments can create financial efficiency
Discover life sciences legal department strategies to boost efficiency and cut costs
Pulse on MedTech: How the industry is adapting to thrive
Current MedTech industry analysis on dealmaking, financing and commercial strategies, with insights on growth, AI, consumer and future state.
Election aftermath: implications for life sciences companies
Join our webcast to explore the 2024 election’s impact on life sciences with insights on drug prices, supply chain and more. Register now!
How one health care testing company gets results with AI
By leveraging AI and automation, patient diagnostics have picked up pace in a health care testing company. Learn more in this case study.
EY webcast: Shaping the future of health equity
In this webcast, panelists discuss findings from the EY Health Equity Outlook Report, exploring the evolution and future of health equity practices.
How life sciences CIOs can make the most of GenAI investments
Optimism about GenAI is spreading among CIOs of life sciences organizations, which must focus on key priorities to benefit from the technology. Read more.
Transforming compliance with advanced strategies and technologies
Learn how multinationals are approaching compliance challenges and driving advancements. Read the 2024 Global Integrity Report – US edition.
Pulse of the MedTech Industry report 2024
2024 EY MedTech report on dealmaking, financing, and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.
How Bayer is unearthing agronomy's future with generative AI
Read this case study to learn how Bayer Crop Science is using large language models to plant the seeds of the future.
Beyond Borders: EY Biotechnology Report 2024
New EY biotechnology report with deal, financing and other data, plus insights on AI, GLP-1 drugs, oncology breakthroughs, the VC lens and much more.
Case study: Accelerated clinical trial activation at UCSD MCC
This case study shows how Moores Cancer Center implemented EY Clinical Trial Fast Lane to accelerate trial activation and access to novel therapies
How strategic partnerships can benefit life sciences companies
Understanding and addressing the VAT and customs aspects of strategic partnerships are essential. Learn more.
How pharma can benefit from using GenAI in drug discovery
Using GenAI in drug discovery is a hot topic in the pharmaceutical industry, with speed and cost savings seen as potential benefits. Learn more.
How ecosystems transform customer journeys
Discover how an EY-orchestrated ecosystem can help companies create differentiated customer journeys.
How life sciences can make the right deals in a time of change
Life sciences companies are returning to dealmaking amid cost and revenue pressures – how will they find the right deals to secure value? Learn more.
How generative AI can optimize health care supply chains
Technology lets organizations capture efficiencies and improve patient care. Find out more.
How tech and trust transformed a tax operating model
Global pharmaceutical player Boehringer Ingelheim is reimaging its tax operating model to boost quality and efficiency. Learn more in this case study.
Why supply chain cost reduction has become a boardroom discussion
A multitude of challenges are reshaping the way COOs think about their supply chains, with cost transformation and resiliency leading the way. Learn more.
Why digital supply chain visibility should be a pharma priority
With digitally driven end-to-end supply chain visibility, pharma companies will be better prepared for the next major supply chain disruption. Learn more.
Redesigning operating models to drive life sciences excellence
Life sciences leaders face an evolving market landscape. Our operating model insights drive agility and resiliency. Read more.
How digital is changing the tax strategy for MedTech
As MedTech companies make substantial investments in digital technology, there are important tax implications that should be addressed. Learn more.
5 steps life sciences companies can take now to build resiliency
Life sciences executives focus on cost containment and agility in the face of economic and legislative challenges. Learn more.
How Bayer became a preferred partner of clinical trial sites globally
For pharma, becoming a preferred clinical trial partner is all about leveraging tech to drive efficiencies and improve site relationships. Read more.
How a life sciences leader accelerated its DEI journey
Leading DEI strategies for biopharmas that boost productivity, governance and talent retention. Read more.
2024 Health Equity Outlook Report
See how much progress has been made toward advancing health equity and read insights on trends and challenges in the 2024 EY Health Equity Outlook Report.
What pharma supply chain transformation means for tax
Businesses looking to create visibility and resilience in their supply chains must loop in tax and transfer pricing teams early in the process. Learn more.
Drive commercial success by effectively navigating loss of exclusivity
Pharmaceutical companies facing patent expiration must carefully craft the right brand strategy to increase value. Learn more.
How digital helps pharma manufacturers drive operational excellence
Transform your pharma manufacturing operations with a digital-first approach
Key steps for improving biopharma expansion into new markets
As biopharma companies look to new markets for needed growth, leaders need to tailor the expansion approach to the nuances of each market. Learn more.
What if your people were the unrealized answer to value creation?
Boost M&A success in life sciences by safeguarding and prioritizing key leaders and employees.
EY leaders in the Life Sciences industry
Direct to your inbox
Stay up to date with our Editor's picks newsletter.